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Abstract
Intrauterine and perinatal factors have been linked to risk of
childhood leukemia, testicular cancer, and breast cancer in the
offspring. The pool of stem cells in target tissue has been
suggested as a critical factor linking early life exposures to
cancer. We examined the relation between intrauterine
hormone levels and measurements of stem cell potential in
umbilical cord blood. Cord blood donors were 40 women, ages
>_18 years, who delivered, from August 2002 to June 2003, a
singleton birth after a gestation of at least 37 weeks. We assayed
plasma concentrations of estradiol, unconjugated estriol,
testosterone, progesterone, prolactin, sex hormone binding
globulin, insulin-like growth factor-I (IGF-I), and IGF binding
protein-3. For stem cell potential, we measured concentrations
of CD34+ and CD34+CD38 cells and granulocyte-macrophage
colony-forming unit (CFU-GM). We applied linear regression
analysis and controlled for maternal and neonatal character-
istics. We found strong positive associations between IGF-I and
stem cell measures, 1 SD increase in IGF-I being associated with
a 41% increase in CD34+ (P = 0.008), a 109% increase in
CD34+CD38 (P = 0.005), and a 94% increase in CFU-GM (P =
0.01). Similar associations were observed for IGF binding
protein-3. Among steroid hormones, estriol and testosterone
were significantly positively associated with CD34+ and CFU-GM.
These findings indicate that levels of growth factors and
hormones are strongly associated with stem cell potential in
human umbilical cord blood and point to a potential
mechanism that may mediate the relationship between
in utero exposure to hormones and cancer risk in the offspring.
(Cancer Res 2005; 65(1): 358-63)
Introduction
It has long been established that many chemicals can lead to
prenatal carcinogenesis in several animal species (1, 2). In humans,
prenatal exposures to ionizing radiation have been shown to cause
leukemia and other tumors in children (3, 4), whereas intrauterine
exposure to diethylstilbestrol has been found to cause vaginal ad-
enocarcinoma in young women (5) and possibly testicular cancer in
men (6). Evidence linking endogenous, rather than exogenous,
perinatal factors to cancer risk in the offspring is more tenuous.
Animal studies have implicated intrauterine hormonal expo-
sures and maternal diet in breast cancer risk of the female rat
offspring (7, 8), whereas in humans most of the relevant evidence
concerns also breast cancer and stems from the fairly consistent
association between birth weight and the risk of this disease in
the offspring (9–14). Positive associations of birth weight, however,
have been reported with several other cancers in the offspring,
including childhood leukemia (15, 16), prostate cancer (17, 18),
and, indeed, cancer overall (19).
The indicated link between birth weight and cancer risk in
the offspring, as well as the strong positive association of insulin-
like growth factor-I (IGF-I) with birth weight (20–22) and the
relation of IGF-I with the risk of several forms of adult cancer (23–25),
brings forward a simple hypothesis that has been implicitly con-
sidered by several investigators searching for common conditions
or processes that may underlie cancer risk (26–29). According
to this hypothesis, articulated by Trichopoulos and Lipworth
(30), growth hormones in intrauterine life, such as IGF-I and ste-
roid hormones, are positively associated with total number of
stem cells and, by extension, total number of replicating im-
mature cells and eventually number of cells at risk for malignant
transformation.
Among stem cells, those with hematopoietic potential are the
only ones that are both identifiable and easily accessible in the
cord blood. We report here the findings on the relation between
measures of hematopoietic stem cell potential and plasma con-
centrations of estrogens, progesterone, prolactin, sex hormone bind-
ing globulin (SHBG), IGF-I, and IGF binding protein-3 (IGFBP-3) in
cord blood.
Materials and Methods
Study Subjects. Subjects were participants in the American Red Cross
(ARC) cord blood program that harvests and stores hematopoietic stem
cells from umbilical cord blood for transplantation purposes. Eligible
participants were pregnant women (ages z18 years) who delivered a
singleton birth (gestational age z37 weeks) at the University of
Massachusetts Memorial Medical Center and St. Vincent’s Hospital. Those
who reported drug use, blood diseases, cancer, AIDS, sexual diseases, or
serious infectious diseases were excluded. Each participant signed a Human
Subjects Committee–approved informed consent form before collection of
cord blood. Among the participants in the ARC program, our study subjects
were identified from those whose cord blood samples collected were not
accepted for storage in the cord blood bank mainly due to insufficient
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volume (<85 mL) or incomplete information on the label of the collection
bag (e.g., missing exact time of delivery).
As a part of the protocol, extensive medical and family history data were
obtained from the participants before delivery. Specifically, women were
asked to self-report their age, race, education, number of prior pregnancies
and live births, and complications during pregnancy in addition to detailed
information of their family medical history. After delivery, a nurse collected
and reported labor and delivery data to the ARC, including the weight and
gestational age of the baby. We obtained information of these maternal and
neonatal characteristics from the ARC database.
The study protocol was approved by the institutional review boards
of the ARC, University of Massachusetts Medical School, University of
Massachusetts Memorial Medical Center, and St. Vincent’s Hospital.
Human Umbilical Cord Plasma and Stem Cell Samples. Umbilical
cord blood was collected from infants delivered according to standard
obstetric practices, while the placenta was still in utero . For infant births
requiring cesarean section, cord blood was collected after the delivery
of the placenta. Cord blood was drained from the umbilical vein using
a 16-gauge needle and was collected in a plastic bag containing 35 mL
citrate-phosphate-dextrose anticoagulant (Baxter Health Care, Deerfield,
IL). After collection, cord blood samples were stored at room tem-
perature and were processed within 24 hours from the time of blood
collection.
Nucleated cell counts were measured in the whole cord blood sample
with an automated Coulter STKS (Beckman-Coulter, Hialeah, FL). The cord
blood samples were centrifuged at 20jC for 30 minutes at 1,400 rpm, and
plasma from each sample was separated. Aliquots containing a total of 2 mL
plasma in each cryovial were prepared and stored at 70jC until the time
of analysis.
After withdrawing plasma, the remaining specimen was diluted 4-fold
with PBS-EDTA solution (Dulbecco’s PBS/5 mmol/L EDTA/2% FCS) and
layered onto lymphocyte separation medium (ICN Biomedicals, Inc., Aurora,
OH) density gradients to deplete RBC. Light-density (U < 1.077 g/mL)
mononuclear cells (MNC) were collected, diluted with PBS-EDTA solu-
tion, and centrifuged at 1,200 rpm for 10 minutes. After erythrocyte
lysis, the cell pellet was washed twice with PBS-EDTA solution and once
with PBS solution (Dulbecco’s PBS/2% FCS) and resuspended in PBS
solution. For flow cytometric analysis, stem cell samples were prepared
after dilution to a concentration between 1  106 and 2  106 cells per
microliter.
HormoneAssays. Hormone assays were conducted at the ILAT Steroid
RIA Laboratory, Department of Physiology, University of Massachusetts
Medical School, and hormone levels were measured in umbilical cord
plasma. Estradiol was measured by RIA using kits from Diagnostic Systems
Laboratories, Inc. (Webster, TX). Testosterone was measured by solid-phase
125I RIA using kits from Diagnostic Products Corp. (Los Angeles, CA).
Unconjugated estriol, progesterone, prolactin, and SHBG were measured
using chemiluminescent immunoassay methodologies from Diagnostic
Products. IGF-I and IGFBP-3 were measured by immunoradiometric assay
using kits obtained from Diagnostic Systems Laboratories.
Samples were assayed in three batches. For each assay run, two aliquots
from each of the three in-house control samples formed by pooled sera were
assayed. The interassay and intra-assay coefficient variations of the in-house
controls were 12.5% and 4.3% for estradiol, 5.2% and 1.6% for testosterone,
6.3% and 6.3% for estriol, 9.5% and 5.9% for progesterone, 6.6% and 1.7% for
prolactin, 9.1% and 4.8% for SHBG, 11.3% and 7.8% for IGF-I, and 6.3% and
12.7% for IGFBP-3, respectively. For each assay, control samples that
accompanied the kit were also examined; all results were within the
manufacturer’s specifications.
Flow Cytometric Analysis of Stem Cell Populations. We mea-
sured currently recognized, standard populations of hematopoietic stem
cells, notably CD34+ and CD34+CD38 (31, 32). Stem cell samples were
incubated with appropriate cocktails of antibodies including anti-CD34
FITC and anti-CD38 phycoerythrin (Becton Dickinson, San Jose, CA) for 30
minutes on ice. This staining process allows simultaneous multicolor
analysis to identify CD34+ and CD34+CD38 cell populations. Following
wash with PBS solution to remove unbound antibodies, the cells were fixed
in 10% paraformaldehyde, stored at 4jC overnight, and analyzed by a
multilaser flow cytometer (FACSCalibur, Becton Dickinson). Results are
expressed as density (concentration) of CD34+ and CD34+CD38 cells per
1,000 MNC.
CD34+ Cell Isolation and Colony-Forming Assay. Primitive progen-
itor cells have the ability to form colonies in vitro in semisolid and liquid
Table 1. Summary of the maternal and newborn
characteristics and the laboratory measurements
Variables n (mean F SD or %) Range
Subject characteristics
Mother’s age (y) 40 (29.6 F 5.0) 18-39
Race of mother and
biological father
Both Caucasian 36 (90.0)
Both African American 1 (2.5)
Both Hispanic 1 (2.5)
Caucasian, Hispanic 1 (2.5)
Caucasian, Asian 1 (2.5)
No. previous live births
0 14 (35.0)
1 13 (32.5)
2 7 (17.5)
3 6 (15.0)
Gestation duration (wk) 40 (39.6 F 1.4) 36.5-41.6
Gender of the baby
Male 21 (53.9)
Female 18 (46.2)
Birth weight
of the baby (g)
39 (3,313.1 F 450.6) 2,500-4,570
Hormones
Estradiol (ng/dL) 40 (792.4 F 733.1) 40.6-3,271.0
Unconjugated
estriol (ng/mL)
40 (281.8 F 115.8) 18.1-516
Testosterone (ng/mL) 40 (1.4 F 0.6) 0.3-3.4
SHBG (nmol/L) 40 (24.7 F 9.0) 11.7-52.0
Progesterone (ng/mL) 40 (214.3 F 110.0) 77.2-525.7
Prolactin (ng/mL) 40 (236.8 F 108.4) 50.8-555.4
IGF-I (ng/mL) 40 (68.3 F 40.3) 10.2-170
IGFBP-3 (ng/mL) 40 (1,040.2 F 278.4) 640-1,644
Cord blood cell populations
TNC (counts/AL), 107 39* (86.0 F 47.3) 36.1-252
MNC (counts/AL), 107 39* (42.4 F 19.7) 16.6-112.1
CD34+ cell densityc 40 (34.5 F 17.1) 4.9-77.6
CD34+CD38 cell
densityc/103 MNC
40 (4.0 F 5.9) 0-19.7
CFU-GM colony counts
Mean in five plates 20 (56.1 F 20.8) 19.2-88.4
Density in
MNC/103 MNC
20 (0.84 F 0.47) 0.17-1.46
NOTE: One subject each had unknown information on birth weight
and gender of baby.
*Total blood volume was missing for one sample.
cCell density per 1,000 MNC.
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cultures on stimulation with specific growth factors. The growth of colonies
derived from granulocyte-macrophage colony-forming unit (CFU-GM) by
in vitro colony-forming cell assay characterizes proliferative potential of
stem cells (33, 34). Thus, we measured CFU-GM colonies by a semisolid
culture assay among CD34+ cells isolated from cord blood.
CD34+ cells were isolated on magnetic-activated cell sorting columns
using microbead-conjugated antibodies (MiniMACS system, Miltenyi Biotec,
Bergisch Gladbach, Germany). To determine the number of CFU-
GM colonies, 2,500 sorted cells were plated in 35-mm tissue culture plate
containing 1.5 mL methylcellulose medium (MethoCult GF H4535, Stem Cell
Technologies, Inc., Vancouver, British Columbia, Canada). Plates were incu-
bated at 37jC in humidified 5% CO2 for 14 days. Colonies that contained
z40 cells were enumerated using a dissecting microscope (Olympus,
Melville, NY) in five plates for each of 20 samples. Based on the mean
of colony counts from five plates, results are expressed first as density of CFU-
GMcolony counts among the CD34+ cells and then as number of CFU-GMper
1,000 MNC.
Statistical Analysis. Descriptive statistics on the characteristics of
study population and laboratory data were calculated. Spearman rank
correlation coefficients were estimated for bivariate analyses. Multivariate
linear regression was used to examine the association between hormones
(independent variable) and natural log-transformed measures of stem cell
potential (dependent variable), adjusting for maternal and neonatal
characteristics (mother’s age, race of parents, number of live births, gestation
duration, baby’s gender and birth weight, and delivery time). Maternal age,
gestational duration, and birth weight were treated as continuous variables.
The fitted coefficients from the regression analyses were exponentiated to
obtain the estimated proportional change in outcome associated with each
independent variable. Statistical significance was set at 0.05 (two-sided). To
conduct statistical analyses, the SAS program version 8.0 (SAS Institute, Cary,
NC) was used.
Results
Among the cord blood samples collected by the ARC cord blood
program from August 2002 to June 2003, we assayed 40 samples.
With the exception of birth weight, the study samples were similar
to all ARC donors on all maternal and newborn characteristics.
Mean birth weight was lower in babies of the study donors than in
those of the ARC donors overall (mean F SD, 3,313 F 451 versus
3,524 F 464 g), because the study samples included cord blood not
accepted for banking by the ARC for volumes that were insufficient
for clinical purposes.
Summary statistics on maternal and newborn characteristics,
plasma concentrations of hormones, and measures of stem cell
potential in umbilical cord blood are presented in Table 1. The
majority (90%) of the cord samples were from neonates of parents
who were both Caucasian. One third of the samples were from the
first live birth. Birth weight ranged from 2,500 to 4,570 g, with a
slightly higher proportion (12.8%) of the subjects classified as
small-for-gestation age (<10th percentile for gestational age) and
only 1 (2.6%) subject as large-for-gestation age (>90th percentile)
based on U.S. singleton births by race and gender (35). Slightly
more than half (53.9%) of the samples were from male neonates.
Mean plasma concentration of estradiol, unconjugated estriol,
testosterone, progesterone, prolactin, and IGF-I were 792 ng/dL,
282 ng/mL, 1.4 ng/mL, 214 ng/mL, 237 ng/mL, and 68.3 ng/mL,
respectively. Mean SHBG and IGFBP-3 concentrations were 25
nmol/L and 1,040 ng/mL, respectively. As measures of stem cell
potential, mean density of CD34+ and CD34+CD38 per 1,000 MNC
were 34.5 and 4.0, respectively. CFU-GM assays were successfully
completed for 20 samples. Mean CFU-GM count in five plates was
56.1 and density of CFU-GM per 1,000 MNC was 0.84. Table 2
presents the results of mutual associations among total nucleated
cell counts (TNC), MNC, and measures of stem cell potential. TNC
and MNC were highly correlated, but neither TNC nor MNC were
associated with stem cell potential as evaluated through densities
of CD34+, CD34+CD38, and CFU-GM. The three measures of stem
cell potential were, as expected, positively and significantly
intercorrelated (Table 2).
Bivariate analysis of associations between plasma hormone levels
and measures of stem cell potential is presented in Table 3. Among
the studied endocrine compounds, estradiol, estriol, testosterone,
Table 2. Spearman correlation coefficients (Ps)
among cord blood cell populations
Variables MNC CD34+ CD34+
CD38
CFU-GM
TNC 0.77
(<0.0001)
0.18 (0.27) 0.07 (0.69) 0.20 (0.42)
MNC 0.18 (0.27) 0.20 (0.23) 0.06 (0.82)
CD34+ 0.43 (0.005) 0.77 (<0.0001)
CD34+CD38 0.49 (0.03)
NOTE: TNC (cell counts/AL of cord blood); MNC (cell counts/AL of cord
blood); CD34+, CD34+CD38, and CFU-GM: density per 1,000 MNC.
Table 3. Spearman correlation coefficients (Ps) between cord blood hormones and cell populations
Variables TNC MNC Measures of stem cell potential, counts/1,000 MNC
CD34+ CD34+CD38 CFU-GM
Estradiol 0.24 (0.13) 0.20 (0.21) 0.30 (0.06) 0.47 (0.002) 0.63 (0.003)
Estriol 0.32 (0.05) 0.31 (0.06) 0.36 (0.02) 0.23 (0.15) 0.63 (0.003)
Testosterone 0.20 (0.23) 0.20 (0.21) 0.30 (0.06) 0.15 (0.35) 0.69 (0.0008)
SHBG 0.03 (0.87) 0.04 (0.80) 0.08 (0.62) 0.30 (0.06) 0.27 (0.25)
Progesterone 0.20 (0.23) 0.14 (0.38) 0.15 (0.37) 0.34 (0.03) 0.39 (0.09)
Prolactin 0.35 (0.03) 0.32 (0.05) 0.13 (0.43) 0.16 (0.32) 0.34 (0.14)
IGF-I 0.24 (0.15) 0.05 (0.75) 0.33 (0.04) 0.20 (0.21) 0.61 (0.004)
IGFBP-3 0.50 (0.001) 0.27 (0.10) 0.37 (0.02) 0.36 (0.02) 0.64 (0.002)
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and the strongly intercorrelated IGF-I and IGFBP-3 (r = 0.70) seem
to be associated with measures of stem cell potential. These results
do not, however, take into account potential confounding influence
of maternal and neonatal characteristics.
The associations between measures of stem cell potential and
the studied hormones in cord blood after adjustment for maternal
and neonatal characteristics are presented in Table 4. Statistically
significant positive associations with all three measures of stem
cell potential are evident with respect to IGF-I and these positive
associations are reflected in similar associations with IGFBP-3.
Weaker associations of stem cell potential are also noted with
respect to estradiol, estriol, and testosterone, whereas for SHBG,
progesterone, and prolactin the evidence for a positive association
with stem cell potential is even weaker.
Discussion
In this study, we have found that IGF-I and IGFBP-3 are
significant predictors of stem cell potential in cord blood. Cord
blood estrogens and testosterone were also positively associated
with stem cell potential, although the respective relations seemed
to be weaker than those of IGF-I and IGFBP-3. We interpret
these findings as indicating that growth hormones during the
perinatal period tend to increase the number of stem cells and, by
extension, the total number of replicating immature cells
susceptible to malignant transformation. Thus, the findings of this
study, which explores an issue that has not been evaluated
previously in humans, point to potential mechanisms that may
underlie prenatal origin of cancer risk at several sites in the
offspring (36).
The working hypothesis for this research is that the size of the
pool of stem cells, which is largely determined during the perinatal
period, is associated with cancer risk (26–28, 37–39). Methodologic
and ethical complexities do not allow a direct testing of the pos-
tulated mechanism in human subjects, as it is difficult to examine
the effects of fetal exposure to pregnancy hormones on stem cell
quantity and on the subsequent occurrence of cancer in the off-
spring. It is also not feasible in a study in humans to use specimens
from fetal organs to study the association between hormone levels
and stem cell quantity. To overcome these constraints, we have
exploited the unique accessibility of cord blood as a human fetal tissue
to examine the relation between intrauterine hormone levels and
measurements of stem cell potential.
Levels of various hormones in the cord blood have been ex-
amined in earlier research (40, 41). Among the hormones examined
by Shibata et al. (40), the geometric mean was 662 ng/dL for
estradiol, 65.0 ng/mL for IGF-I, and 696 ng/mL for IGFBP-3 in the
cord blood plasma from 57 Caucasian subjects. In another study,
the mean was 26 ng/dL for testosterone, 12,420 pg/mL for estradiol,
and 249 ng/mL for estriol in the cord blood sera from 86 subjects of
different races (f60% Caucasian; ref. 41). Our results on estradiol
and IGF-I were very similar to that found in Shibata et al. (40),
but our findings on testosterone, estradiol, and estriol were
not directly comparable with that in Troisi et al. (41) due to the
difference in type of samples (plasma versus sera) and in racial
composition of the subjects.
Although hematopoietic stem cells may not share all properties
of organ-specific stem cells, they are by definition largely
undifferentiated. CD34 antigen is an integral membrane glycopro-
tein of 90 to 120 kDa and is considered as one of the defining
hallmarks of hematopoietic stem cells (42). However, the CD34+
population is heterogeneous and includes differentiating cells,
committed progenitor cells, early multipotent progenitors, and
stem cells, whereas CD34+CD38 and CFU-GM cells are more
primitive subpopulations (31, 33, 34, 42). It is of interest to note
that the regression coefficients linking cord blood estrogens,
testosterone, and IGF-I to stem cell potential tend to be smaller for
CD34+ cells that include more differentiated cells.
We consider it important that the strongest associations with
cord blood stem cell potential were found with IGF-I and its
strongly correlated binding protein IGFBP-3. IGFs and their
binding proteins are recognized as important factors in carcino-
genesis (43). IGF-I and IGFBP-3 have been shown in a recent meta-
analysis to be associated with increased risks of non-smoking-
related cancers in epidemiologic studies (44). It may also be of
importance that IGF-I in the fetus is regulated by metabolic factors
rather than being significantly influenced by growth hormone as in
Table 4. Multiple linear regression analysis for the association between measures of stem cell potential and
hormone levels in cord blood
Hormones % Change (95%
confidence interval)
P % Change (95%
confidence interval)
P % Change (95%
confidence interval)
P
CD34+ cells/103 MNC CD34+ CD38 cells/103 MNC CFU-GM counts/103 MNC
Estradiol 9.5 (11.8 to 35.9) 0.40 38.0 (9.8 to 111.2) 0.13 31.3 (9.6 to 90.3) 0.14
Estriol 30.5 (8.8, 56.4) 0.006 34.4 (10.4 to 101.4) 0.15 39.6 (1.3, 92.4) 0.04
Testosterone 22.6 (1.6, 47.9) 0.04 30.5 (12.4 to 94.4) 0.18 37.2 (1.6, 85.1) 0.04
SHBG 1.4 (22.0 to 24.5) 0.90 53.1 (1.8 to 138.7) 0.06 66.8 (8.4, 156.8) 0.02
Progesterone 7.4 (14.2 to 34.3) 0.52 51.1 (1.6 to 132.1) 0.06 11.2 (24.9 to 64.7) 0.56
Prolactin 4.0 (25.2 to 23.3) 0.74 21.1 (52.1 to 29.9) 0.34 46.3 (4.3 to 123.7) 0.07
IGF-I 40.9 (10.0, 80.5) 0.008 108.8 (27.6, 241.7) 0.005 93.6 (19.6, 213.4) 0.01
IGFBP-3 32.3 (5.0, 66.7) 0.02 97.3 (26.3, 208.1) 0.004 47.6 (0.5 to 119.0) 0.05
NOTE: Frommultiple regression model, adjusting for mother’s age, race of parents, number of live births, gestation duration, gender of baby, delivery time,
and birth weight of baby. % Change: expected proportional change in dependent variable associatedwith 1 SD increase per independent variable. Ps for the
estimated coefficients.
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adult life (45), that IGF-I cannot cross the placenta (46), and that
cord blood levels of IGFBP-3 are positively correlated with those
of IGF-I (47).
In addition to questions concerning the degree of similarity
between blood and organ-specific stem cells and to considerations
regarding sample size, particularly with respect to CFU-GM, our
study has another limitation stemming from the cross-sectional
ascertainment of hormone levels and cell populations. Experimental
evidence, however, points to quiescent stem cells proliferating on
stimulation by IGF-I, estrogens, and growth-enhancing hormones
(48–50), so that the directionality of the positive associations
between hormone levels and stem cell potential can reasonably be
inferred. Results from the Dutch Famine Study suggest that caloric
restriction in the third rather than the earlier trimesters reduces
birth weight (51). Thus, it is possible that hormones and growth
factors in late pregnancy influence a subject’s cancer risk through
their effect on birth weight, whereas organogenesis interlinked with
stem cell potential in early gestation might involve a distinct
pathway. A positive correlation between birth weight and CD34+ cell
density (Spearman correlation g = 0.12) was observed in this study,
but sample size constraint did not allow informative analyses that
adjusted properly for covariates in the relation between stem cell
measurements and birth weight.
In conclusion, we have found evidence that IGF-I and IGFBP-3
and, to a lesser extent, estradiol, estriol, and testosterone in the
umbilical cord are positively associated with measures of hema-
topoietic stem cell potential. These findings support a possible link
between increased in utero exposure to IGF-I, estrogens, and
testosterone and increased proliferative potential of stem cells and
suggest a plausible biological mechanism underlying the early life
roots of human cancer. The number of samples in the current
analysis is relatively small, however, and the results should be
replicated in studies with larger samples.
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